

REGENERON PHARMACEUTICALS INC  
Form 4  
November 20, 2012

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
VAGELOS P ROY

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
REGENERON PHARMACEUTICALS INC [REGN]

3. Date of Earliest Transaction (Month/Day/Year)  
11/19/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chairman of the Board

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)				Price
Common Stock	01/12/2012		G	V	3,786	D	\$ 0	167,761	I	by CLAT
Common Stock	03/30/2012		G	V	1,852	D	\$ 0	165,909	I	by CLAT
Common Stock	07/12/2012		G	V	1,860	D	\$ 0	164,049	I	by CLAT
Common Stock	10/09/2012		G	V	1,392	D	\$ 0	162,657	I	by CLAT
	07/24/2012		G <sup>(1)</sup>	V	19,947	D	\$ 0	59,844	I	by GRAT

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock										
Common Stock	07/24/2012		G <sup>(1)</sup>	V	19,947	D	\$ 0	39,897	I	by GRAT
Common Stock	07/24/2012		G <sup>(1)</sup>	V	19,947	D	\$ 0	19,950	I	by GRAT
Common Stock	09/04/2012		G <sup>(1)</sup>	V	19,947	D	\$ 0	3	I	by GRAT
Common Stock	11/19/2012		S		30,800	D	\$ <u>(2)</u>	129,200	I	by Spouse as Trustee <u>(3)</u>
Common Stock	11/19/2012		S		1,700	D	\$ <u>(4)</u>	127,500	I	by Spouse as Trustee <u>(3)</u>
Common Stock								56,946	D	
Common Stock								82,410	I	by GRAT
Common Stock								2,329	I	By 401(k) Plan
Common Stock								15,162	I	by GRAT
Common Stock								1,203	I	by trust for grandch <u>(5)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Code V (A) (D)				

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
VAGELOS P ROY 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	X		Chairman of the Board	

## Signatures

/s/\*\*P. Roy  
Vagelos 11/19/2012

\*\*Signature of Date  
Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) A GRAT of which the reporting person is a donor and trustee distributed to the adult children of the reporting person shares of Regeneron common stock in accordance with the terms of the GRAT.  
Represents volume-weighted average price of sales of 30,800 shares of Company stock on November 19, 2012 at prices ranging from
  - (2) \$160.63 to \$160.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 19, 2012 at each separate price.
  - (3) By an irrevocable trust for the benefit of grandchildren of the reporting person, of which the spouse of the reporting person is trustee.  
Represents volume-weighted average price of sales of 1,700 shares of Company stock on November 19, 2012 at prices ranging from
  - (4) \$161.00 to \$161.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 19, 2012 at each separate price.
  - (5) By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.